Lavinia (Ethinylestradiol, Levonorgestrel)

The ethinylestradiol component provides estrogenic activity that stabilises the uterine lining, while levonorgestrel acts as a progestogen to suppress the mid‑cycle luteinising hormone surge, thereby preventing ovulation. Together they thicken cervical mucus and alter the endometrium, making fertilisation and implantation unlikely.

The dosing regimen for Lavinia is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and duration are individualized based on the patient’s clinical needs.

Lavinia is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it may cause fetal harm. It is also not recommended for use while breastfeeding, as hormonal exposure could affect milk production and infant health.

To order Lavinia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lavinia contains the standard dose combination of ethinylestradiol and levonorgestrel, which is comparable to many other COC products. Its efficacy, safety profile and side‑effect spectrum are similar to alternative brands that use the same active ingredients, though formulation excipients may differ.

Lavinia tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Lavinia is taken orally as a tablet. It can be swallowed with or without food, but it should be taken at the same time each day to maintain consistent hormone levels and optimal contraceptive effectiveness.

Serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction and severe allergic reactions. Women with a history of clotting disorders, smoking over age 35, or uncontrolled hypertension are at higher risk and should avoid the product.

Lavinia is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.